Analysts’ Weekly Ratings Changes for Tandem Diabetes Care (TNDM)

Several analysts have recently updated their ratings and price targets for Tandem Diabetes Care (NASDAQ: TNDM):

• 10/13/2026 – Tandem Diabetes Care was given a new $18.00 price target by Mizuho.
• 10/7/2026 – Tandem Diabetes Care was upgraded by Barclays PLC to “hold”.
• 10/6/2026 – Tandem Diabetes Care is now covered by Barclays PLC. They set a “positive” rating and a $18.00 price target on the stock.
• 9/30/2026 – Tandem Diabetes Care had its price target lowered by Citigroup Inc. from $24.00 to $20.00. They now have a “neutral” rating on the stock.
• 9/24/2026 – Tandem Diabetes Care had its price target lowered by Truist Financial Corporation from $31.00 to $28.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Tandem Diabetes Care had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 8/21/2026 – Tandem Diabetes Care is now covered by William Blair. They set an “outperform” rating on the stock.

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.